Product Name: Dact3 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, WB
Applications: Dact3 antibody can be used for detection of Dact3 by Western blot at 1 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: Dact3 antibody was raised against a 17 amino acid synthetic peptide from near the amino terminus of human Dact3.The immunogen is located within amino acids 370 – 420 of Dact3.
Host Species: Rabbit
Purification: Dact3 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 1231930-82-7
Product: LY2835219
Buffer: Dact3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: Dact3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Dact3 Antibody: RRR1, DAPPER3, RRR1, Dapper homolog 3, Antagonist of beta-catenin Dapper homolog 3
Accession NO.: Q96B18
Protein Ino: 119368655
Official Symbol: DACT3
Geneid: 147906
Background: Dact3 Antibody: The Wnt signaling cascade is a conserved process in multicellular animals that plays important roles during development and can contribute to cancer and other diseases. Many members of this pathway are also expressed in the postnatal tissues such as brain. One such protein is Dact3, a member of the Dact protein family that was initially identified through binding to Disheveled (Dvl), a cytoplasmic protein essential to Wnt signaling. Dact3 is expressed in the ventral region of maturing somites, limb bud and branchial arch mesenchyme, embryonic CNS, and the adult brain. Recent evidence shows that Dact3 acts as a negative regulator Wnt/beta-catenin signaling that is repressed at the transcriptional level in colorectal cancer and this repression is associated with bivalent histone modifications. This repression can be reversed by pharmacological agents that targets both histone methylation and deacetylation, suggesting that Dact3 may be a potential target for therapeutic treatment of this cancer. At least three isoforms of Dact3 are known to exist.
PubMed ID:http://aac.asm.org/content/38/2/315.abstract
